VINC — Vincerx Pharma Cashflow Statement
0.000.00%
- $0.07m
- -$4.37m
- 15
- 57
- 12
- 16
Annual cashflow statement for Vincerx Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.12 | -39.3 | -65.4 | -40.2 | -30.1 |
| Depreciation | |||||
| Non-Cash Items | -0.054 | 0.27 | 6.73 | 3.84 | 4.07 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.008 | 5.61 | -1.02 | -4.19 | -0.178 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.165 | -33.4 | -59.6 | -40.5 | -26.1 |
| Capital Expenditures | — | -0.258 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -65.6 | -5 | -40.6 | 41.5 | 0.212 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -65.6 | -5.26 | -40.6 | 41.5 | 0.212 |
| Financing Cash Flow Items | 0.603 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 66.5 | 88.5 | 0.28 | 0.114 | 18 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.66 | 49.8 | -99.8 | 1.12 | -7.79 |